Literature DB >> 15605187

Frequency and antimicrobial resistance of gram-positive bacterial pathogens from bloodstream infections in the Czech Republic.

P Cermák1, M Kolár, T Látal, B Heinigeová, N Bartoníková.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 15605187     DOI: 10.1007/s10096-004-1208-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  5 in total

1.  Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals.

Authors:  F Luzzaro; E F Viganò; D Fossati; A Grossi; A Sala; C Sturla; M Saudelli; A Toniolo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-12-11       Impact factor: 3.267

2.  Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management.

Authors:  Erik L Munson; Daniel J Diekema; Susan E Beekmann; Kimberle C Chapin; Gary V Doern
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

3.  Diagnosis of vascular catheter-related bloodstream infection: a meta-analysis.

Authors:  Y Siegman-Igra; A M Anglim; D E Shapiro; K A Adal; B A Strain; B M Farr
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

4.  Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program.

Authors:  S A Marshall; W W Wilke; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1998-03       Impact factor: 2.803

5.  Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

Authors:  M A Pfaller; R N Jones; G V Doern; K Kugler
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.